The Barmer study: Impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus

Current Medical Research and Opinion

Volumn 30, Issue 5, 2014, Pages 753-760

  Pfutzner A ^a   Hermanns, N ^b   Funke, K ^c   Forst, T ^d   Behnke, T ^d   Bitton, G ^e   Nagar, R ^f   Raz, I ^g   Haak, T ^b  

^a IKFE Institute for Clinical Research and Development   (Germany)

^b Research Institute of the Diabetes Academy Mergentheim (FIDAM)   (Germany)

^c IKFE Potsdam   (Germany)

^d Profil Mainz   (Germany)

^e Diabetes Research Center   (Germany)

^f InsuLine Medical Ltd   (Israel)

^g HEBREW UNIVERSITY   (Israel)

Author keywords

Injection site warming device; Insulin therapy; Prandial insulin dose; Rapid acting insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG ABSORPTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; WARMING;

ABSORPTION; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; OBESITY; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES;

EID: 84895758159     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.880049     Document Type: Article

References (23)

1. Magerl W, Treede RD. Heat-evoked vasodilatation in human hairy skin: Axon reflexes due to low-level activity of nociceptive afferents. J Physiol 1996;497(Pt 3):837-48
2. Minson CT, Berry LT, Joyner MJ. Nitric oxide and neurally mediated regulation of skin blood flow during local heating. J Appl Physiol 2001;91:1619-26
3. Kellogg Jr DL. In vivo mechanisms of cutaneous vasodilation and vasoconstriction in humans during thermoregulatory challenges. J Appl Physiol 2006;100:1709-18
4. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J 1980;280:1411-13
5. Raz I, Weiss R, Yegorchikov Y, et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, twoperiod, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther 2009;31:980-7
6. Raz I, Yegorchikov Y, Bitton G, et al. Improving pharmacokinetic and pharmacodynamic profiles of rapid-acting insulin analogs using the InsuPatch device. J Diabetes Sci Technol 2009;3:384.A138
7. Cengiz E, Tamborlane W, Sherr J, et al. Effect of a novel warming device on pharmacodynamics (PD) of rapid acting insulin in youth with type 1 diabetes (T1D). Diabetes Technol Ther 2011;13:173-293
8. Freckmann G, Pleus S, Westhoff A, et al. Clinical performance of a device that applies local heat to the insulin infusion site: A crossover study. J Diabetes Sci Technol 2012;6:320-7
9. Freckmann G, Pleus S, Haug A, et al. Increasing local blood flow by warming the application site: Beneficial effects on postprandial glycemic excursions. J Diabetes Sci Technol 2012;6:780-5
10. Anderson Jr JH, Brunelle RL, Keohane P, et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 1997;157:1249-55
11. Danon A, Ben-Shimon S, Ben-Zvi Z. Effect of exercise and heat exposure on percutaneous absorption of methyl salicylate. Eur J Clin Pharmacol 1986;31:49-52
12. Ashburn MA, Ogden LL, Zhang J, et al. The pharmaco-kinetics of transdermal fentanyl delivered with and without controlled heat. J Pain 2003;4:291-7
13. Sindelka G, Heinemann L, Berger M, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994;37:377-80
14. Jakobsen LA, Jensen A, Larsen LE, et al. Effect of cutaneous blood flow on absorption of insulin: A methodological study in healthy male volunteers. Int J Physiol Pathophysiol Pharmacol 2011;3:257-65
15. DCCT. Hypoglycemia in the Diabetes Control and Complications Trial. The Control and Complications Trial Research Group. Diabetes 1997;46:271-86
16. DCCT. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995;18:1415-27
17. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995;44:968-83
18. Anderson Jr JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulinanalog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-70
19. Pfützner A, Küstner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996;104:25-30
20. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12
21. Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 2011;14:665-71
22. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health 2006;9:193-8
23. Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm 2010;16:264-75.